Anixa Biosciences Inc. has announced the initiation of dosing in the fourth cohort of its ongoing Phase 1 clinical trial for a novel CAR-T therapy targeting recurrent ovarian cancer. This cohort will receive a dose of three million CAR-positive cells per kilogram, which is thirty times higher than the initial dose administered in the first cohort. The trial, conducted in partnership with Moffitt Cancer Center, aims to evaluate the safety and therapeutic potential of this treatment. No dose-limiting toxicities were observed in the previous cohort, allowing the progression to this higher dose. The study is currently focused on safety and determining the maximum tolerated dose, with promising early signs of potential efficacy. Results from this study are yet to be presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.